← Back to patent-cliff list
Ferric Pyrophosphate Citrate
Tier C — Watch / tradeFerric Pyrophosphate Citrate
Rockwell Medical Inc
Originator
2015
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Not applicable
Brand：Triferic
Indications (approved)：Chronic renal impairment, 血红蛋白病, Anaemia, Iron deficiency anaemia, End-stage renal disease, Renal impairment
Regional status
US
Withdrawn
EU
-
China
Phase III
2021-01-04
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Ferric Pyrophosphate Citrate?
Approved indications include: Chronic renal impairment, 血红蛋白病, Anaemia, Iron deficiency anaemia, End-stage renal disease, Renal impairment.
When does the Ferric Pyrophosphate Citrate patent expire?
No public expiry year is available for Ferric Pyrophosphate Citrate yet; this page updates once verified.
How do I get a quote for Ferric Pyrophosphate Citrate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-19